Literature DB >> 21666533

Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus.

Rashed A Hasan1, Edmund OʼBrien, Peter Mancuso.   

Abstract

OBJECTIVE: To measure levels of 8-isoprostane and Lipoxin A4 in the exhaled breath condensate of children (7-17 yrs old) recovering from status asthmaticus in a pediatric intensive care unit and to compare their respective levels in the exhaled breath condensate collected from age-matched "healthy" children enrolled from an ambulatory pediatric clinic during well-child visits.
DESIGN: Prospective case-controlled study.
SETTING: Teaching hospitals and a research laboratory. PATIENTS: Children recovering from status asthmaticus and age-matched controls.
INTERVENTIONS: Collection of exhaled breath condensate from patients recovering from status asthmaticus and controls for purpose of measurement of 8-isoprostane and Lipoxin A4.
MEASUREMENTS AND MAIN RESULTS: There was no difference in age (11.9 ± 3.0 vs. 12.0 ± 3.3 yrs, p = .9) between patients and control subjects. All participants completed the exhaled breath condensate collection without complications. There was no difference in the pulmonary index (3.3 ± 2.2 vs. 3.1 ± 1.9, p = 1.0) after collection of exhaled breath condensate compared with baseline values in patients with status asthmaticus. The level of 8-isoprostane was significantly higher (63 ± 9 vs. 41 ± 13 pg/mL, p < .001), whereas the level of Lipoxin A4 was significantly lower (5.6 ± 2.9 vs. 10.5 ± 3.1 ng/mL, p < .001) in the exhaled breath condensate from children recovering from status asthmaticus compared with control subjects.
CONCLUSIONS: 8-Isoprostane was elevated and Lipoxin A4 is decreased in the exhaled breath condensate of children recovering from status asthmaticus in a pediatric intensive care unit. These data may provide new insight into the pathophysiology of asthma in children in this clinical setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21666533      PMCID: PMC4078922          DOI: 10.1097/PCC.0b013e3182231644

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  27 in total

Review 1.  Exhaled markers of pulmonary disease.

Authors:  S A Kharitonov; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

2.  Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics.

Authors:  M Sanak; B D Levy; C B Clish; N Chiang; K Gronert; L Mastalerz; C N Serhan; A Szczeklik
Journal:  Eur Respir J       Date:  2000-07       Impact factor: 16.671

3.  Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages.

Authors:  C Godson; S Mitchell; K Harvey; N A Petasis; N Hogg; H R Brady
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

4.  Lipid mediator class switching during acute inflammation: signals in resolution.

Authors:  B D Levy; C B Clish; B Schmidt; K Gronert; C N Serhan
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

5.  Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes.

Authors:  Levente József; Christine Zouki; Nicos A Petasis; Charles N Serhan; János G Filep
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

6.  Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4).

Authors:  Bruce D Levy; George T De Sanctis; Pallavi R Devchand; Eugene Kim; Kate Ackerman; Birgitta A Schmidt; Wojciech Szczeklik; Jeffrey M Drazen; Charles N Serhan
Journal:  Nat Med       Date:  2002-08-12       Impact factor: 53.440

7.  Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations.

Authors:  E Baraldi; S Carraro; R Alinovi; A Pesci; L Ghiro; A Bodini; G Piacentini; F Zacchello; S Zanconato
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

8.  Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma.

Authors:  Rosalia Gagliardo; Pascal Chanez; Marc Mathieu; Andreina Bruno; Giorgia Costanzo; Claire Gougat; Isabelle Vachier; Jean Bousquet; Giovanni Bonsignore; Antonio M Vignola
Journal:  Am J Respir Crit Care Med       Date:  2003-07-31       Impact factor: 21.405

9.  Endogenous airway acidification. Implications for asthma pathophysiology.

Authors:  J F Hunt; K Fang; R Malik; A Snyder; N Malhotra; T A Platts-Mills; B Gaston
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

10.  Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.

Authors:  C N Serhan; C B Clish; J Brannon; S P Colgan; N Chiang; K Gronert
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

View more
  12 in total

Review 1.  Targeting pro-resolution pathways to combat chronic inflammation in COPD.

Authors:  Steven Bozinovski; Desiree Anthony; Ross Vlahos
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

Review 2.  Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation.

Authors:  Melody G Duvall; Thayse R Bruggemann; Bruce D Levy
Journal:  Mol Aspects Med       Date:  2017-05-17

3.  Exhaled breath condensate eicosanoid levels associate with asthma and its severity.

Authors:  Shamsah Kazani; Anna Planaguma; Emiko Ono; Matteo Bonini; Muhammad Zahid; Gautham Marigowda; Michael E Wechsler; Bruce D Levy; Elliot Israel
Journal:  J Allergy Clin Immunol       Date:  2013-04-19       Impact factor: 10.793

4.  Traffic-related air pollutants and exhaled markers of airway inflammation and oxidative stress in New York City adolescents.

Authors:  Molini M Patel; Steven N Chillrud; K C Deepti; James M Ross; Patrick L Kinney
Journal:  Environ Res       Date:  2012-11-23       Impact factor: 6.498

Review 5.  DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation.

Authors:  Melody G Duvall; Bruce D Levy
Journal:  Eur J Pharmacol       Date:  2015-11-03       Impact factor: 4.432

Review 6.  Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases.

Authors:  Rafael I Jaén; Sergio Sánchez-García; María Fernández-Velasco; Lisardo Boscá; Patricia Prieto
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

7.  Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways.

Authors:  Bruce D Levy
Journal:  Front Immunol       Date:  2012-12-28       Impact factor: 7.561

Review 8.  Innate immunity is a key factor for the resolution of inflammation in asthma.

Authors:  Cindy Barnig; Bruce D Levy
Journal:  Eur Respir Rev       Date:  2015-03

9.  LC-MS/MS Determination of Isoprostanes in Plasma Samples Collected from Mice Exposed to Doxorubicin or Tert-Butyl Hydroperoxide.

Authors:  Monika Janicka; Agata Kot-Wasik; Jolanta Paradziej-Łukowicz; Grażyna Sularz-Peszyńska; Agnieszka Bartoszek; Jacek Namieśnik
Journal:  Int J Mol Sci       Date:  2013-03-18       Impact factor: 5.923

10.  Airway oxidative stress in chronic cough.

Authors:  Heikki O Koskela; Minna K Purokivi
Journal:  Cough       Date:  2013-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.